X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase's validated oncology targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARase Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 18, 2023
Details:
During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Uppthera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 06, 2022
Details:
During the three-year collaboration, multiple undisclosed targets (including undruggable targets) were screened against HitGen’s proprietary DNA encoded chemical libraries (DELs). The majority of the targets have resulted in confirmed novel potent hits.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mitsubishi Tanabe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 25, 2022
Details:
HitGen has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Identified compounds will be exclusively licensed to UPPTHERA for further development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: UPPTHERA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 28, 2021
Details:
HitGen and Merck have expand their collaboration with a license to develop a novel class of drugs for an early target of high interest. HitGen will grant exclusive rights to Merck & Co., Inc Kenilworth, NJ USA to develop and commercialize the licensed compounds.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2020
Details:
Baiyunshan will get exclusive rights to develop and market HG030 in mainland China, and will pay HitGen an upfront licensing fee and a series of milestones and royalty of sales as the product progresses through clinical trials and launches in the mainland China.
Lead Product(s): HG030
Therapeutic Area: Oncology Product Name: HG030
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guangzhou Baiyunshan Pharmaceutical Holdings
Deal Size: Undisclosed Upfront Cash: $5.8 million
Deal Type: Licensing Agreement November 10, 2020
Details:
Multiple small molecule leads for an undisclosed target nominated by Almirall were the subject of this achievement. HitGen will grant exclusive rights to Almirall for further development and commercialization, and be eligible for preclinical and clinical milestone payments.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 26, 2020
Details:
Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morphic Therapeutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2020
Details:
HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to identify small molecule leads against targets of interest to Evotec SE in the field of anti-infectives.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
